Merck's Erbitux cancer drug meets primary target in first-line phase III study |
|
|
|
Published
:
Wed, 04 Apr 2007 07:44 |
FRANKFURT (AFX) - Merck KGgaA said its cancer drug Erbitux combined with platinum-based chemotherapy has met a primary endpoint in a first-line phase III head and neck cancer study.The primary endpoint, or objective, was to increase overall survival in patients with recurrent and or metastatic head and neck cancers, said the company in a statement.krysia.diver@afxnews.comkd/icCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|